Status: Not yet recruiting
Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)
This study will evaluate efficacy and tolerability various doses of belantamab mafodotin in combination with cevostamab and pomalidomide in patients with multiple myeloma who have relapsed disease after two or more lines of therapy and/or have refractory to treatment disease.
Participants needed: 108
Trial details
Phase: Phase 1Age: 18-100Biological sex: AllType: InterventionalSponsor: Canadian Myeloma Research GroupUpdated: Sep 21, 2026Locations: 7
Eligibility criteria
Must be able to understand and voluntarily sign an informed consent form (ICF). [+22]
Prior treatment with bispecific or BCMA targeted antibody drug conjugate. Note p... [+41]